eli lilly compound tirzepatide asks to join lawsuit over compounded versions of its weight-loss drugs US judge denies injunction, restricting

GLP-1 treatments may be particularly beneficial for those patients who are overweight or obese and have associated conditions such as type 2 diabetes or significant cardiovascular risk factors

In the SURPASS clinical trials for type 2 diabetes, constipation was reported in approximately 12-17% of patients taking tirzepatide, with rates varying by dose

These effects were associated with hemolytic anemia in pregnant women [14]

Tablets are the standard: swallowed, absorbed through the gut

Not through any Amazon listing this article could confirm as brand-authorized

As payer oversight continues to increase, GLP-1 coding will remain a high-impact, high-risk area that requires careful attention to detail and constant policy updates.